Could exposure to the coronaviruses that cause the common cold help protect against COVID-19?


Could exposure to the coronaviruses that cause the common cold help protect against COVID-19?

Is herd immunity closer than previously thought?

As nations lift lockdowns and experts worry about a potential second peak in cases, our ability to ward off infection is one of the hottest topics of scientific debate.

Ever since it became apparent that children were less vulnerable to COVID-19 early in the pandemic, scientists have speculated that the regular spread of benign viruses in places like schools could have bolstered their immune response to the latest coronavirus.

Now the idea of “cross immunity” among the broader population is gaining some ground.

In a recent post on Twitter, Francois Balloux of University College London noted an “intriguing” lack of an immediate resurgence in COVID-19 cases following the easing of lockdowns in several countries.

Among the possible explanations, he noted, were seasonality and enduring social distancing practices.

But he posited a “wilder” hypothesis as well—that a “proportion of the population might have pre-existing immunity to #SARSCoV2, potentially due to prior exposure to ‘common cold’ coronaviruses”.

Balloux said that might explain issues like cases where there is no transmission between spouses.

Earlier this month, an American study in the journal Cell suggested between 40 and 60 percent of the population could be immunized against COVID-19 without ever being exposed to it.

Researchers put this down to the action of protective cells, known as T lymphocytes, that had been activated by other coronaviruses responsible for colds.

But authors Alessandro Sette and Shane Crotty, of La Jolla Institute for Immunology, cautioned that the research did not suggest the epidemic was running out of steam.

“Clearly some individuals are more susceptible to the disease than others; after being infected some individuals have severe clinical symptoms and might even die, while others might show very little in terms of clinical symptoms,” they told AFP by email.

“Our study suggests that preexisting immunity might be one of the factors to be considered; but at this point is simply an hypothesis that needs to be addressed with further experiments.”

‘Jury out’

The World Health Organization has also expressed caution over the issue.

“There is certainly some evidence with regard to T cells, that if you have a previous coronavirus infection you may be able to mount a more rapid response to COVID-19,” said the WHO’s Michael Ryan at a press conference this week.

“But there’s no empirical evidence that previous coronavirus infections protect you from infection with COVID-19. The jury is still very much out on that,” he added.

However, Ryan said it was an encouraging sign for the development of vaccines.

“It gives us hope that we are getting the kinds of immune responses that may be helpful to long-term protection,” he said.

New waves?

Another uncertainty is whether everyone is equally vulnerable to catching COVID-19.

A growing number of scientists think maybe not, raising questions over assumptions for what is known as herd immunity.

Gabriela Gomes, a researcher at the Liverpool School of Tropical Medicine, told AFP that it was wrong to assume that one person is as susceptible to the virus as another, or as exposed.

“We know little about the factors which underlie this individual variation. It could be cross-immunity with other coronaviruses, but it could also be other microbes, genetics, age, behaviour, and most likely a combination of many factors,” she said.

In theory this could explain why early estimates of the proportion of individuals who have been infected by the new coronavirus have been lower than expected – at around 5 to 10 percent of the total population in several countries.

It could also mean a lower threshold for herd immunity – when a sufficient part of the population has caught the virus, starving it of new hosts to spread to and thereby stopping the epidemic.

This threshold, commonly accepted as around 60 to 70 percent of the population infected, is what Sweden hoped to achieve by deciding against a strict lockdown.

But Gomes said that mathematical models on herd immunity often “ignore individual variation”.

According to a study she co-authored, which has not yet been peer reviewed, the threshold might be reached when just 10 to 20 percent of the population has been infected.

Gomes said her research, which simulated the lifting of social distancing measures over the next six to 12 months, suggested that even if countries that had been severely affected are “closer to herd immunity”, they would still see more localised outbreaks.

There could also be “what may seem like a second wave in those countries that have been less affected so far”.

At the Pitie-Salpetriere hospital in Paris, professor of emergency medicine Yonathan Freund has noticed a sharp drop in the number of infections among doctors compared with the start of the epidemic.

“This is pure speculation but it could mean that people have natural or acquired immunity,” he told AFP.

It is giving him confidence.

With infections staying low three weeks after France lifted its strict lockdown measures, he thinks that could mean “the second wave is not coming and probably will not happen” in the country.

COVID-19 infection is the biggest threat today for survival of the human race. It has a faster spread and has increased mortality rate than the other influenza viruses. Individuals who are elderly or who have underlying chronic health problems are at a higher risk of mortality.

A dysregulated and enhanced immune response called cytokine storm than the virus itself is described to produce respiratory failure, acute respiratory distress syndrome (ARDS) and multiple organ dysfunction syndrome (MODS) leading to death in these patients [1].

Human body has two types of immunity called type 1 or type 2 immunity invoked through Th1 cells and Th2 cells to rationalize virtually all the known patterns of immune response.

Th1 cells are known to be induced by intracellular pathogens like Mycobacteria, Salmonella, leishmaniasis, viruses, etc. These are involved in evoking the classic delayed-type hypersensitivity (DTH) skin response to viral and bacterial antigens, and fight cancer cells. T

h2 cells are believed to emphasize protection against extracellular pathogens such as multicellular parasites. The Th1 pathway is often portrayed as being the more aggressive of the two and release various proinflammatory cytokines like IL1, IL2, IL12, TNF-α, IFN-γ, etc. while the Th2 pathway is seen to release various anti-inflammatory cytokines like IL4, IL5, IL6, IL10, etc. which are also involved in several allergen-specific and related IgE-based events like development of airway eosinophilia, the induction of airway smooth muscle contraction, mucus production, etc. and also predisposing to several systemic autoimmune diseases [2–5].

Factors like malnutrition, overcrowding, vitamin D deficiency, etc. are also known to induce Th2 immunity which in turn downregulates the available Th1 immunity [6–9].

The vast majority of elderly population in developed nations like Italy or USA, due to their less exposure to various infective antigens, have reduced Th1 immunity [10]. The stock of their naïve T cells too remains in the age-related relatively dysfunctional state.

It is important to note that COVID-19 has inflicted high morbidity and mortality to only that segment of the world population, [11] which has low Th1 immunity due to poor or no exposure to strong Th1 antigens like Mycobacteria, Salmonella, even Bee stings, etc.

COVID-19 has been seen to affect more of those countries who have robust and free influenza vaccination program leading to reduced natural flu infection among their population [12–14].

Immunity from disease often follows a single natural exposure to it, while immunity from vaccines usually develops after several doses only. The natural flu infection is known to provide better immunity and protection with higher antibody (IgA) level than after the flu vaccination.

This is attributed to the different route of antigen presentation. Intramuscular route of vaccination fails to induce antibodies which can only be produced after mucosal viral replication in mucosal cells of the respiratory tract in natural infection [15].

Another possible reason for this viral outburst could be adaption to an unnatural way of life, depriving it of such a common and natural Th1 immunity of common flu.

Influenza virus is uniquely characterized by frequent mutations due to antigenic drifts and antigenic shifts. To ensure optimal vaccine efficacy against prevailing strains, the antigenic composition of the vaccine is revised twice annually in both the northern hemisphere (NH) and southern hemisphere (SH), and contemplates likely antigenic characteristics of the continuously changing future mutations of viruses within the WHO Global Influenza Surveillance and Response System (GISRS).

WHO recommends influenza vaccine with different strains for the NH and SH. Is it not strange that influenza vaccine, meant for those living in northern hemisphere, is also available and being used in India, while WHO recommendations on vaccine formulation for India strongly favour the Southern hemisphere vaccine rather than the one for Northern hemisphere? [16].

Immunization rate against influenza is significantly higher in high-income (92%) than in low-income countries (8–47%) [12]. Higher cost of the influenza vaccine, its adverse effects and rapid change in nature and epidemiology of the virus are reported to be the cause for its poor coverage among the south Asian population [17].

The poor flu vaccination coverage among our population too has unknowingly helped the society to maintain its natural immunity and fight better with this global enemy COVID-19.

Countries like Italy, Spain, Germany etc. with very low prevalence of tuberculosis and where the routine BCG immunization has been discontinued since decades, [18–20] are witnessing the worst form of this global epidemic of Corona virus [11].

A relatively elderly population of these countries with many co-morbid conditions is slated to be the possible explanation for such an occurrence but their low Th1 immunity due to the stray past exposure to various infectious antigens, particularly the Mycobacteria, cannot be just ignored which could be further substantiated with the relatively low COVID-19 deaths in countries like India, Indonesia, Vietnam and Nigeria [11].

BCG is the live attenuated vaccine used against tuberculosis prepared from M. bovis bacillus. It is one of the most widely used vaccines and is part of national vaccine program of more than 154 countries.

BCG is estimated to be given to more than 100 million children per year globally and, thus, has a well-established safety profile. BCG, besides providing specific protection against tuberculosis, has the capacity to confer relatively broad-spectrum protection against other pathogens also like candida, staphylococcus, etc. [21].

BCG provides this broad spectrum or the cross protection by making certain changes in specific genes of circulating monocytes or the natural killer (NK) cells [22, 23]. These changes can be considered memory like responses in innate immunity cells, which, otherwise, are part of adaptive immunity only.

BCG-vaccinated children have not only shown decreased mortality rate associated with malaria, diarrhea, attenuated yellow fever virus, etc. [24], but also have shown reduced risk of developing acute lower respiratory tract infections also in separate studies [25, 26].

BCG vaccination has also shown reduced respiratory infection in many RCTs in adults and in the elderly population as well [27, 28]. Protective effect of BCG wanes with time and is reported to disappear completely in 10–15 years [29].

Countries with policy of compulsory BCG vaccination at birth, therefore, may provide protection to their population from childhood tuberculosis but the continued collateral benefits like what is being contemplated during the present COVID-19 pandemic are possible only through the environmental exposure to Mycobacteria as seen in the tubercular high burden countries.

It has been shown that influenza provides significant protection against the Mycobacterial infection [30]. It is possible that a reciprocal cross immunity exists between the two pathogens and will be the most deserving need of the hour at a time when the whole world is struggling to fight with the Corona outbreak.

Any modality of treatment or prophylaxis of even a meagre hope would be worth a trial of its clinical application. Mice coinfected with BCG and influenza A virus exhibited reduced frequency and numbers of CD8 T cells specific to Mycobacterium (BCG) in the lungs when compared with mice infected with BCG alone.

Viral-specific CD8 T cells were seen to have special affinity towards BCG-induced granulomas resulting in substantial accumulation of viral-specific CD8 T cells there [31]. Such an affinity can be made to be used in patients with COVID-19 to divert and subvert its overactive immune response towards BCG granulomas.

It may be inferred that deployment of BCG-specific CD8 T cells will occur at the cost of viral-specific CD8 T cells, thus reducing the magnitude of cytokine storm of the Corona infection.

Acute viral infections like influenza or COVID-19 normally result in the formation of short-lived, but highly functional, terminally differentiated effector Th1 cells that eliminate infected target cells [32]. Influenza virus in an experimental study on mice has shown to be lethal only if it is able to induce a combined Th1 and Th2 response [33].

Similarly, cytokine storm with very high levels of diverse cytokines profile with mixed Th1/Th2 affinity like IL2, IL7, IL10, GCSF, IP10, MCP1, MIP1A, and TNFα were seen in ICU patients than non-ICU patients of COVID-19 infection. What prompts this unusual Th2 response in these patients could be the key to understand and evolve protective measure against this huge threat to humanity [34].

Another study comparing immunological profile of mild or severe COVID-19 patients, low levels of CD4 + T and CD8 + T and very high levels of IL-6 and IL-10 were reported in severe COVID-19 patients [35]. Mycobacteria is one of the strongest antigens to induce Th1 immunity [36]; while, Salmonella has also been considered a model pathogen for inducing strong Th1 response [37].

Vaccination of both of these pathogens shall restore the forgotten and decreased Th1 immunity among the immunologically useful antigen starved population of the developed nations, shall downregulate the Th2 bias environment of cytokine storm with IL6 and, thus, help reducing local tissue destruction in COVID-19 patients [38].

BCG-specific CD4+ T-cell response is reported to be peaked 6–10 weeks after vaccination [39]. BCGs prophylactic use, therefore, may not yield instant protection as desirable, yet is a tool with little possibility to lose but enormous possibility of gains.

Under the present circumstances, when developing a new specific vaccine against COVID-19 may take years to reach the target population, BCG can prove to be a good stop gap measure and may actually prove miraculous.

Considering its wide and easy availability, considering its low cost, excellent safety profile and considerable non-specific immunogenicity including possible cross immunity against influenza, BCG vaccine should be considered for its prophylactic usage against COVID-19 in high-risk health professionals and the elderly population besides the use of chloroquine [40].

It is suggested that a study of critically ill patients of COVID-19 be undertaken in high prevalence tuberculosis countries like ours to measure their level of immunity against Mycobacteria through Mantoux tuberculin skin test or interferon-gamma release assays (IGRAs).

A relatively low-test reading among these patients than those of the general population shall support the hypothesis that population with low or no immunity against Mycobacteria are more prone to COVID-19 infection and shall possibly benefit with BCG vaccine.


1. Mehta P, Mc Auley DF, Brown M, et al. Covid-19, consider cytokine storm syndromes and immunosuppression. Lancet. 2020 doi: 10.1016/S0140-6736(20)30628-0. [PubMed] [CrossRef] [Google Scholar]

2. Roitt I, Brostoff J, Male D. Immunology (Fifth Edition) Philadelphia: Mosby; 1998. [Google Scholar]

3. Wang L, Cai Y, Cheng Q, Hu Y, Xiao H. Imbalance of Th1/Th2 cytokines in patients with pulmonary tuberculosis. Zhonghua Jie He He Hu Xi Za Zhi. 2002;25(9):535–537. [PubMed] [Google Scholar]

4. Collins FM. Cellular antimicrobial immunity. Critical Reviews in Microbiology. 1979;7:27–91. doi: 10.3109/10408417909101177. [PubMed] [CrossRef] [Google Scholar]

5. Bretscher PA. An hypothesis to explain why cell-mediated immunity alone can contain infections by certain intracellular parasites and how immune class regulation of the response can be subverted. Immunology and Cell Biology. 1992;70:343–351. doi: 10.1038/icb.1992.44. [PubMed] [CrossRef] [Google Scholar]

6. Strachan DP. Allergy and family size: a riddle worth solving. Clinical and Experimental Allergy. 1997;27:235–236. doi: 10.1111/j.1365-2222.1997.tb00699.x. [PubMed] [CrossRef] [Google Scholar]

7. González-Torres C, González-Martínez H, Miliar A, et al. Effect of malnutrition on the expression of cytokines involved in Th1 cell differentiation. Nutrients. 2013;5:579–593. doi: 10.3390/nu5020579. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

8. Neyestani TR, Woodward WD, Hillyer L. Serum levels of Th2-type immunoglobulins are increased in weanling mice subjected to acute wasting protein-energy malnutrition. Iranian Journal of Allergy, Asthma and Immunology. 2004;3:1–6. [PubMed] [Google Scholar]

9. Salahuddin N, Ali F, Hasan Z, Rao N, Aqeel M, Mahmood F. Vitamin D accelerates clinical recovery from tuberculosis: results of the SUCCINCT Study (Supplementary Cholecalciferol in recovery from tuberculosis). A randomized, placebo-controlled, clinical trial of vitamin D supplementation in patients with pulmonary tuberculosis’ BMC Infectious Diseases. 2013;19:22. doi: 10.1186/14712334-13-22. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

10. Okada H, Feillet H, Bach J-F. The “hygiene hypothesis” for autoimmune and allergic diseases: an update. Clinical and Experimental Immunology. 2010;160(1):1–9. doi: 10.1111/j.1365-2249.2010.04139.x. [PMC free article] [PubMed] [CrossRef] [Google Scholar]11. Covid-19 coronavirus pandemic. Available and collected on 30th March 2020 from

12. Principi N, Camilloni B, Esposito S. Influenza immunization policies: Which could be the main reasons for differences among countries? Human Vaccines and Immunotherapeutics. 2018;14(3):684–692. doi: 10.1080/21645515.2017.1405188. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

13. Di Pietro A, Visalli G, Antonuccio GM, Facciola A. Today’s vaccination policies in Italy: The national plan for vaccine prevention 2017–2019 and the Law 119.2017 on the mandatory vaccinations. Annali di Igiene. 2019;31(2 suppl 1):54–64. [PubMed] [Google Scholar]

14. Panatto D, Lai PL, Mosca S. Influenza vaccination in Italian healthcare workers (2018–2019 Season): strengths and weaknesses. Results of a cohort study in two large Italian hospitals. Vaccines. 2020;8:119. doi: 10.3390/vaccines8010119. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

15. Chan K-H, To Kelvin KW, Hung Ivan FN, et al. Differences in antibody responses of individuals with natural infection and those vaccinated against Pandemic H1N1 2009 influenza. Clinical and Vaccine Immunology. 2011;18(5):867–873. doi: 10.1128/CVI.00555-10. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

16. Thakre R, Patil PS. Influenza vaccine paradox. Indian Paediatrics. 2019;56:80. doi: 10.1007/s13312-019-1567-6. [PubMed] [CrossRef] [Google Scholar]

17. Wiwanitkit V. Influenza vaccination: some clinical concerns for South Asian practitioner. Ind J Med Res. 2019;150(2):107–109. doi: 10.4103/ijmr.IJMR_1291_19. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

18. Zwerling et al (2011) The BCG world atlas: a database of global vaccination policies and practices. PLos Medicine 8(3) [PMC free article] [PubMed]

19. Faust L, Schreiber Y, Bocking N. A systemic review of BCG vaccination policies among high risk groups in low TB-burden countries. BMC Public Health. 2019;19:1504. doi: 10.1186/s12889-019-7868-9. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

20. Global tuberculosis report (2019) WHO’s global tuberculosis database. Covian C, Fernandez-Fierro A, Retamal-Díaz A, et al. BCG-induced cross-protection and development of trained immunity: implication for vaccine design. Frontiers in Immunology. 2019;29:2806. doi: 10.3389/fimmu.2019.02806. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

22. Netea MG, van Crevel R. BCG-induced protection: effects on innate immune memory. Seminars in Immunology. 2014;26(6):512–517. doi: 10.1016/j.smim.2014.09.006. [PubMed] [CrossRef] [Google Scholar]

23. Arts RJW, Carvalho A, La Rocca C, Palma C, Rodrigues F, Silvestre R, et al. Immunometabolic pathways in BCG-induced trained immunity. Cell Reports. 2016;17:2562–2571. doi: 10.1016/j.celrep.2016.11.011. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

24. Roth A, Gustafson P, Nhaga A, Djana Q, Poulsen A, Garly ML, Jensen H, Sodemann M, Rodriques A, Aaby P. BCG vaccination scar associated with better childhood survival in Guinea-Bissau. International Journal of Epidemiology. 2005;34(3):540–547. doi: 10.1093/ije/dyh392. [PubMed] [CrossRef] [Google Scholar]

25. Hollm-Delgado MG, Stuart EA, Black RE. Acute lower respiratory infection among Bacille Calmette- Guérin (BCG)-vaccinated children. Pediatrics. 2014;133(1):e73–81. doi: 10.1542/peds.2013-2218. [PubMed] [CrossRef] [Google Scholar]

26. de Castro MJ, Pardo-Seco J, Martinón-Torres F. Nonspecific (heterologous) protection of neonatal BCG vaccination against hospitalization due to respiratory infection and sepsis. Clinical Infectious Diseases. 2015;60(11):1611–1619. doi: 10.1093/cid/civ144. [PubMed] [CrossRef] [Google Scholar]

27. Wardhana EA, Datau EA, Sultana A, et al. The efficacy of Bacillus Calmette-Guerin vaccinations for the prevention of acute upper respiratory tract infection in the elderly. Acta Medica Indonesiana. 2011;43:185e90. [PubMed] [Google Scholar]

28. Ohrui T, Nakayama K, Fukushima T, et al. Prevention of elderly pneumonia by pneumococcal, influenza and BCG vaccinations. Nihon Ronen Igakkai Zasshi. 2005;42:34e6. doi: 10.3143/geriatrics.42.34. [PubMed] [CrossRef] [Google Scholar]

29. Whittaker E, Nicol MP, Zar HJ, Tena-Coki NG, Kampmann B. Age-related waning of immune responses to BCG in healthy children supports the need for a booster dose of BCG in TB endemic countries. Scientific Reports. 2015;8:15309. doi: 10.1038/s41598-018-33499-4. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

30. Gupta A, Gupta A, Kumar A, Arora S. Immunotherapy for non-responders among patients of spinal tuberculosis. Indian Journal of Tuberculosis. 2016;63(2):79–85. doi: 10.1016/j.ijtb.2015.07.006. [PubMed] [CrossRef] [Google Scholar]

31. Florido M, Grima MA, Gillis CM, et al. Influenza A virus infection impairs Mycobacteria-specific T cell responses and Mycobacterial clearance in the lung during pulmonary coinfection. Journal of Immunology. 2013;2013:191. [PubMed] [Google Scholar]

32. Kahan SM. T cell exhaustion during persistent viral infections. Virology. 2015;479–480:180–193. doi: 10.1016/j.virol.2014.12.033. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

33. Turianova L, Lachova V, Svetlikova D, et al. Comparison of cytokine pro les induced by nonlethal and lethal doses of influenza A virus in mice. Experimental and Therapeutic Medicine. 2019;18:4397–4405. [PMC free article] [PubMed] [Google Scholar]

34. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan China. Lancet. 2020;395(10223):497–506. doi: 10.1016/S0140-6736(20)30183-5. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

35. Wan S, Qingjie YE and Fan S, et al (2020) Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP) MedRxiv. 10.1101/2020.02.10.20021832.

36. Diehl S, Rincon M. The two faces of IL-6 on Th1/Th2 differentiation. Molecular Immunology. 2002;39:531–536. doi: 10.1016/S0161-5890(02)00210-9. [PubMed] [CrossRef] [Google Scholar]

37. Lyadova I, Panteleev AV. Th1 and Th17 cells in tuberculosis: protection, pathology, and biomarkers. Mediators of Inflammation. 2015;2015:854507. doi: 10.1155/2015/854507. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

38. O’Donnell H, MsSorley S. Salmonella as a model for Non-Cognate Th1 cell stimulation. Front Immunology. 2014;5:621. [PMC free article] [PubMed] [Google Scholar]

39. Soares AP, Kwong Chung C, Choice T, et al. Longitudinal changes in CD4+ T-cell memory responses induced by BCG vaccination of newborns. Journal of Infectious Diseases. 2013;207(7):1084–1094. doi: 10.1093/infdis/jis941. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

40. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Research. 2020;30:269–271. doi: 10.1038/s41422-020-0282-0. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

Journal information:Cell


Please enter your comment!
Please enter your name here

Questo sito usa Akismet per ridurre lo spam. Scopri come i tuoi dati vengono elaborati.